single search, OvidMD uncovers the latest treatment options, evidence-based guidelines, and drug therapies, plus users can download customizable patient handouts, link instantly to full text, review articles, and more. Convenient search tools include auto complete, synonym expansion, drawing on Ovid's proprietary controlled vocabulary lexicon to provide hundreds of thousands of medical synonyms, phrase detection, spelling suggestions, and highlighted search terms. Learn more at www.ovidmd.com
The addition of OvidMD to the suite of tools offered by Ovid further strengthens its leading position as the point-of-research for medical institutions, hospitals, and healthcare organizations worldwide. As an aggregator of the world's authoritative, peer-reviewed resources from more than 150 information producers, Ovid provides effective research solutions, including OvidMD and its flagship research platform OvidSP, used by physicians, clinicians, students, researchers, and librarians to make important decisions to improve patient care, enhance ongoing research, and fuel new discoveries.
About Ovid and Wolters Kluwer Health
Ovid® is a global information solutions provider offering clinicians, professionals, students, and researchers in the medical, scientific, and academic fields customizable solutions of content, tools, and services that make research smarter, faster, and more effective. Ovid is used by the world's leading colleges and universities; medical schools; academic research libraries and library consortia; hospitals and healthcare systems; pharmaceutical, engineering and biotechnology companies; and HMOs and clinical practices.
Ovid is part of Wolters Kluwer Health, a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Wolters KluwePage: 1 2 3 4 Related medicine technology :1
. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients2
. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer3
. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain4
. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer5
. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,9476
. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results7
. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice8
. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results9
. Amicus Therapeutics Announces Second Quarter 2007 Financial Results10
. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights11
. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study